Beyond the Drip: Elevating Ig Therapy Through Education and Standards 
Welcome to Beyond the Drip, where we dive into the fascinating world of Infusion Pharmacy, from Home Infusion to Ambulatory Infusion Centers. Expect topical conversations on the latest happenings in Infusion from industry leaders who will bring you the latest news, trends and innovations in the infusion industry, as well as expert insights and stories to keep you informed and inspired.         
In episode 12 of Beyond the Drip, hosts Jon Love, Paula Roth, Brandon Carpenter, Pam McIntyre and Brian O’Sullivan welcome Luba Sobolevski, CEO and founder of IgNS, and Chief Clinical Officer Amy Clarke to discuss the evolving world of immunoglobulin (Ig) therapy and the 14th annual IgNS conference. 
The conversation highlights why IgNS was founded: to fill critical gaps in clinician education and standardize practices for a complex, lifelong therapy. Unlike fields such as oncology, Ig therapy historically offered limited training, leaving nurses and pharmacists underprepared to manage patient care and navigate regulatory and payer requirements. 
The IgNS conference, often called the “Super Bowl” of Ig therapy, brings together every sector of the industry from manufacturers and distributors to clinicians, pharmacists and infusion centers. Attendees can choose from business and clinical tracks, gaining guidance on revenue cycle management, documentation and legally defensible standards of practice. 
The discussion also explores how AI and technology are transforming care, from speech-to-text documentation and data analysis to wearable monitoring, while emphasizing that clinical judgment remains irreplaceable. Patient-focused initiatives, including education and surveys, ensure standards translate into safer, more effective care. 
Key Takeaways: 

• Ig therapy is highly complex, with multiple indications, dosing protocols and routes of administration, creating unique challenges for clinicians and payers. 

• Standardized education and competency frameworks help clinicians deliver safer, patient-centered care. 

• The IgNS conference provides actionable guidance for clinical and revenue cycle professionals, including documentation, prior authorizations and payer collaboration. 

• AI can streamline workflows and enhance decision-making but must be paired with expert clinical oversight. 

• Patient education and feedback are essential to measure the impact of standards on care and outcomes. 

This episode offers insights into how IgNS is advancing Ig therapy standards, supporting clinicians and improving patient care. Listen to the full conversation on Beyond the Drip and subscribe to stay informed on the innovations shaping infusion care. 

Guest Speakers:
Luba Sobolevsky, Pharm.D., IgCP®, President | CEO at Immunoglobulin National Society 
Dr. Luba Sobolevsky is the President and Chief Executive Officer of the Immunoglobulin National Society (IgNS), the central, standards-setting healthcare organization in the field of Ig therapy and biologics. Dr. Sobolevsky has over 25 years of diverse leadership experience across the healthcare field, including clinical practice, education, and pharmaceutical industry. She oversees IgNS’ strategic initiatives and the development of comprehensive programs and resources that promote best clinical practices and optimal patient outcomes. She is responsible for expanding and improving interdisciplinary and industry-wide collaboration and alliances.

Dr. Sobolevsky leads IgNS’ Patient 360 division, dedicated to patient advocacy, education and outcomes research. She has been actively engaged in research and publication in areas of optimizing immunoglobulin practice, patient experience, health equity, healthcare team competencies, and the improvement of screening and...